



GOG Partners History & Structure

Robert L. Coleman, MD
Co-Director, GOG-Partners

Structure





PARTNERS
A GOG Foundation Program




To conduct clinical and translational research that positively impacts women through the prevention and treatment of gynecologic malignancies



To be the premier collaborative network for transformative research in gynecologic malignancies

Our History



Monk, Coleman, Herzog, et al., Gynecol Oncol 2021, *in press*

CONFIDENTIAL – *Not for Release*

Our Leadership



Dr. Larry J. Copeland
President



Directors

Dr. Robert Coleman
Dr. Bradley Monk

Associate Directors

Dr. Thomas Herzog
Dr. Kathleen Moore

Clinical Trial Advisors

Dr. David O'Malley (Ovary)
Dr. Leslie Randall (Cervix)
Dr. Brian Slomovitz (Uterine)
Dr. Ramez Eskander
Dr. Bhavana Pothuri



GOG Foundation Vice President and Group Chair
Dr. Robert Mannel

Gynecologic Cancer Committee Chair
Dr. Carol Aghajanian


Gynecologic Cancer Committee Vice Chair
Dr. Paul DiSilvestro



Contents lists available at [ScienceDirect](#)

Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno



Review Article

The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation

Bradley J. Monk^{a,1}, Robert L. Coleman^{b,*,1}, Thomas J. Herzog^c, Kathleen N. Moore^d, David M. O'Malley^e, Leslie M. Randall^f, Brian M. Slomovitz^g, Ramez Eskander^h, Bhavana Pothuriⁱ, Laura L. Reese^j, Robert S. Mannel^d, Larry J. Copeland^e

Our Management Team

Operations Team

Laura Reese
Executive Director of
Operations

Katie Campbell
Director, GOG Partners
Clinical Trial Management

Jennifer Klein
Director, GOG Partners
Protocol & Regulatory
Compliance

Nicole LaMack
Director of
Grants/Accounting

Communications


Jenna Cummins
Director of Communications &
Industry Relations

Legal Team


Michael Powers
General Counsel

Two On-Staff Attorneys


Where Are We?



GOG Partners Quarterly Accrual - 2 Years




Investigator Council



ENGOT/GOG-Partners


Gynecologic Oncology 154 (2019) 255–258



Contents lists available at [ScienceDirect](#)


Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno



Clinical commentary

Joint ENGOT and GOG Foundation requirements for trials with industry partners[☆]



Ignace Vergote^{a,*,1}, Robert L. Coleman^{b,1}, Sandro Pignata^c, Michael A. Bookman^d, Christian Marth^e, Thomas J. Herzog^f, Antonio Gonzalez-Martin^{g,2}, Larry J. Copeland^{h,2},
on behalf of the European Network of Gynaecological Oncological Trial Groups (ENGOT)
and The GOG Foundation Inc.

^a ENGOT/BGOG and University Hospital Leuven, Gynaecological Oncology, Leuven Cancer Institute, Herestraat 49, 3000 Leuven, Belgium, European Union
^b GOG-F and Gynecologic Oncology & Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
^c ENGOT/MILO Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli, Italy
^d GOG-F and Gynecologic Oncology Therapeutics, Kaiser Permanente San Francisco, San Francisco, USA
^e ENGOT/A-AGO and Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
^f GOG-F and Gynecologic Oncology, University of Cincinnati, Cincinnati, Ohio, USA
^g ENGOT/GEICO and Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain
^h GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA

H I G H L I G H T S

- ENGOT and GOG-Foundation present for the first time the joint requirements for trials with the industry.
- Guidelines are presented for sponsorship, trial steering committee, and development of protocol, database and statistical plan.
- A roadmap is presented for site selection, contracts, press releases, publications and the communication plan.

From Idea



To Success





THANK YOU